Read on Wikipedia

Scientific misconduct is the violation of the standard codes of scholarly conduct and ethical behavior in the publication of professional scientific research. A Lancet review on Handling of Scientific Misconduct in Scandinavian countries provides the following sample definitions,[1] reproduced in The COPE report 1999:[2]

Danish definition: “Intention or gross negligence leading to fabrication of the scientific message or a false credit or emphasis given to a scientist”

Swedish definition: “Intention[al] distortion of the research process by fabrication of data, text, hypothesis, or methods from another researcher’s manuscript form or publication; or distortion of the research process in other ways.”

The consequences of scientific misconduct can be damaging for perpetrators and journal audience[3][4] and for any individual who exposes it.[5] In addition there are public health implications attached to the promotion of medical or other interventions based on false or fabricated research findings.

Three percent of the 3,475 research institutions that report to the US Department of Health and Human Services’ Office of Research Integrity, indicate some form of scientific misconduct.[6] However the ORI will only investigate allegations of impropriety where research was funded by federal grants. They routinely monitor such research publications for red flags and their investigation is subject to a statute of limitations. Other private organizations like the Committee of Medical Journal Editors (COJE) can only police their own members.[7]

The validity of the methods and results of scientific papers are often scrutinized in journal clubs. In this venue, members can decide amongst themselves with the help of peers if a scientific paper’s ethical standards are met.

Let's start with the truth!

Support the Broken Science Initiative.
Subscribe today →

Leave A Comment

recent posts

    If you're seeing this page, you are not currently logged into a profile with access to Affiliate Owners / Medical.

    At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.

    The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.

    An abbreviated version of this discussion is available here, for free.

    At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.

    Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.

    The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.

    An abbreviated version of this discussion is available here, for free.

    MetFix and BSI Members can view the full 54-minute video.